COVID-19 vaccine - Flow Pharma
Alternative Names: FLOVID-20; FlowVax COVID-19 vaccine; SARS-CoV-2-VaccineLatest Information Update: 28 May 2024
At a glance
- Originator Flow Pharma
- Class COVID-19 vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Inhalation, Powder)
- 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (IV, Injection)
- 21 Apr 2020 Flow Pharma has patent protection for peptide particle formulation in Canada, USA, European Union and Australia (Flow Pharma website, before April 2020)